In the Messenger Signal, users can now pin messages in chats. The duration is flexible, but the space for it is limited, as Signal announces. “The most frequently asked questions, restaurant ...

Both desktop apps have been removed from app stores and will stop working in December. Both desktop apps have been removed from app stores and will stop working in December. is a senior editor and ...

Meta is officially deprecating its Windows and Mac support for its Messenger app on December 15, potentially leaving millions of users without a convenient way to converse with friends. Once the ...

Meta has published a support doc that states its Messenger app for Mac is being discontinued. New users won’t be able to download the app at all, and existing users have about 60 more days of use ...

Meta is shutting down Messenger’s stand-alone desktop apps for Windows and Mac on December 15, the company confirmed to TechCrunch on Thursday. Starting December 15, users will no longer be able to ...

If you're using Messenger on macOS, you'll want to switch to something else — and probably sooner, rather than later. According to a pair of Facebook Help Center page, Facebook is axing its Desktop ...

Before everyone had a smartphone in their pocket and access to countless free mobile games (both good and hot messes), people got their free gaming fixes from browser games. I have fond memories of ...

Messenger is one of the most popular messaging services around, especially in the US, but it has its faults. Group chats, for example, are not end-to-end encrypted by default, meaning the company that ...

Contrary to what many of my friends believe, good academics are always working—at least in the sense that when we’re stuck on a problem, which is most of the time, it’s impossible to leave it behind.

Shares of Replimune (NASDAQ:REPL) plunged ~38% in the premarket on Monday after Stat News reported that the FDA’s top regulator of cancer drugs intervened during the review of the company’s lead asset ...

Despite a sharp drop in the previous session following the FDA rejection of its skin cancer drug RP1, Replimune (NASDAQ:REPL) shares bounced back on Wednesday even as multiple Wall Street analysts ...

Replimune Group, Inc. (NASDAQ:REPL) stock plunged on Tuesday after a U.S. Food and Drug Administration (FDA) update. The clinical stage biotechnology company received an FDA Complete Response Letter ...